

Figure 1




Figure 2




Figure 3




Figure 4

Gene expression in LS180 tumours (dose response of 303i after 48 hours)




Figure 5

FIGURE 6(A)




FIGURE 6(B)




Figure 6

BEST AVAILABLE COPY

L I F D R H P I A A L L C Y P

160 161



Site 3

L L

168 169



Site 4

V M




FIGURE 7

BEST AVAILABLE COPY

Tumor Model




FIGURE 8(A)

Treatment Regime






FIGURE 8(B)

BEST AVAILABLE COPY

Tumor Model



Tumor Seeding (i.p.)



TCS (i.p.)

Harvest Organs for In Situ

FIGURE 9(A)

Assessment of Tumor Growth





FIGURE 9(B)

Efficacy of Suicide Gene SPLP

BEST AVAILABLE COPY

INXC TK



CONTROL




FIGURE 9(C)

BEST AVAILABLE COPY




Figure 10

Systemic TK303 Efficacy in the CT26 Tumor Model




FIGURE 11

TK060. Effect of Frameshift construct and TK on tumor volume




FIGURE 12